← All indications
Leukemia, Myeloid, Acute
Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.
Subtype terms (7)
More specific conditions that are subtypes of Leukemia, Myeloid, Acute in the MeSH hierarchy.
- Leukemia, Basophilic, Acute
- Leukemia, Eosinophilic, Acute
54 drugs (41 approved, 13 experimental)
- Leukemia, Erythroblastic, Acute
7 drugs (6 approved, 1 experimental)
- Leukemia, Mast-Cell
27 drugs (20 approved, 7 experimental)
- Leukemia, Megakaryoblastic, Acute
18 drugs (12 approved, 6 experimental)
- Leukemia, Monocytic, Acute
77 drugs (53 approved, 24 experimental)
- Leukemia, Promyelocytic, Acute
35 drugs (24 approved, 11 experimental)
Drugs by status
Approved for this indication (21)
Phase 4 trials (40)
- fludarabine
- cyclosporine
- allogeneic bone marrow
- mercaptopurine
- stem cells
- ciprofloxacin
- micafungin
- 23-valent pneumococcal polysaccharide vaccine
- inactivated influenza vaccine
- Anti-thymocyte Globulin (Rabbit)
- cladribine
- amlodipine
- interferon alpha-2b
- venetoclax
- sorafenib
- Filgrastim
- amsacrine
- topotecan
- etoposide
- sargramostim
- decitabine
- cyclophosphamide
- indigo
- ruxolitinib
- autologous hematopoietic stem cells
- azacitidine
- imatinib
- lenalidomide
- flumatinib
- ceftazidime
- +10 more
Phase 3 trials (114)
- dociparstat
- elacytarabine
- ondansetron
- jnj-75276617
- t-cell depleted hsv-tk engineering donor lymphocytes
- carvedilol
- vadastuximab talirine
- galinpepimut-s
- morphine
- ganetespib
- thiotepa
- metoclopramide
- xy0206
- zarnestra
- oblimersen sodium
- cd123/cll1 car-t cells
- treosulfan
- bortezomib
- bone marrow derived mesenchymal stem cells
- chlorhexidine
- nalbuphine
- carlecortemcel-l
- pevonedistat
- alemtuzumab
- triptorelin
- sklb1028
- allogeneic lymphocytes
- sodium chloride
- dexrazoxane
- selinexor
- +84 more
Phase 2 trials (411)
- anti-cd19/20-car vector-transduced t cells
- magnesium sulfate
- balixafortide
- bp1001
- ocv-501
- mik665
- midazolam
- dordaviprone
- salsalate
- vemurafenib
- tirelizumab
- bsb-1001
- cd3/cd28 stimulated t cells
- hm43239
- astx029
- lp-118
- fish oil
- pravastatin
- tgrx-814
- mgta-145
- ab8939
- edetic acid
- cytokine induced killer cells
- spironolactone
- monalizumab
- ard103
- cd45-depleted allogenic peripheral blood stem cell
- levetiracetam
- triciribine
- acetylcysteine
- +381 more
Phase 1 trials (432)
- regorafenib
- inkt cells
- bms-214662
- tak-901
- zoledronic acid
- ionis-stat3rx
- kx2-391
- tetanus-cmv fusion peptide vaccine
- kpt-9274
- rd-iit-001
- sc-daric33
- ags67e
- tigecycline
- ar-42
- b7-h3 target, car gene modified gdt cell injection
- apx001
- idelalisib
- tas1440
- dimethylarsinous glutathione
- allo-revcar01-t
- jnj-63709178
- neoantigen reactive t cells
- amg-900
- trx103
- moxifloxacin
- tanespimycin
- rem-422
- rgi-2001
- pf-06747143
- gamma-delta t cells
- +402 more
Other trials (30)
- tegafur
- avm0703
- zinc
- pemetrexed
- foscarnet
- jnj-28312141
- gl-onc1
- thalidomide
- tranexamic acid
- gimeracil
- oteracil
- parthenolide
- valganciclovir
- tetanus toxoid
- interferon alpha-1
- um-171
- gm-csf secreting leukemia vaccine
- sheng-yu-tang
- metronidazole
- pyrithione
- cd56 car-t cells
- g-749
- adrenomedullin (22-52)
- nkg2d car-nk
- dendritic cell activated lymphocyte
- ganciclovir
- allogeneic blood cells
- leukocyte antigen-mismatched g-pbscs
- car-γδt
- deferoxamine
Organizations
Organization Involved with Phase 4 Indications (23)
- Peking University
- Southern Medical University
- Cornell University
- Shantou University
- University of Valencia
- Meda
- Changhai Hospital
- University of Gothenburg
- PETHEMA Foundation
- Jilin University
- Guangzhou Medical University
- Universidad Complutense de Madrid
- University of London
- Russian Academy of Medical Sciences
- Sun Yat-Sen University
- Medical College of Wisconsin
- Soochow University
- Dalian Medical University
- Technical University of Dresden
- EpiCept Corporation
- Jiao Tong University
- Fujian Medical University
- Universidad Autonoma de Barcelona
Organization Involved with Phase 3 Indications (182)
- Changzhou No.2 People's Hospital
- Gottfried Wilhelm Leibniz Universität Hannover
- University of Lyon
- University of Hamburg
- Free University of Amsterdam
- The Christie NHS Foundation Trust
- Sellas Life Sciences Group
- Actinium Pharmaceuticals
- Gruppo Italiano Trapianto di Midollo Osseo
- The First People's Hospital of Lianyungang
- National Marrow Donor Program
- Kanisa Pharmaceuticals
- Sanofi
- Government of Russia
- Shandong Province Qianfoshan Hospital
- Delta-Fly Pharma, Inc.
- Jazz Pharmaceuticals
- Millennium Pharmaceuticals
- The Leukemia and Lymphoma Society
- Copernicus Memorial Hospital
- AbbVie
- Nanjing University
- Albert Einstein Israelite Hospital
- University of Washington
- Chinese Academy of Medical Sciences
- Weifang Medical University
- Helsinn
- Central Hospital, Zibo
- Southwest Oncology Group
- Duke University
- +152 more
Organization Involved with Phase 2 Indications (309)
- Monter Cancer Center
- Bristol-Myers Squibb
- Bambino Gesù Hospital and Research Institute
- Sungkyunkwan University
- New York Medical College
- Chung-Ang University
- University of California, San Francisco
- Clear Creek Bio, Inc.
- University of Minnesota
- University of Rostock
- F2G Ltd.
- Children's National Medical Center
- Technical University of Munich
- NewLink Genetics Inc
- AZ Sint-Jan
- SGX Pharmaceuticals
- Konkuk University
- University of Cincinnati
- inVentiv
- Pennsylvania State University
- Hebrew University
- ALFA cooperative Group
- IQVIA
- Pavlov First Saint Petersburg State Medical University
- Fujifilm
- University of Rochester
- Emory University
- Suzhou Yasheng Pharmaceutical Co., Ltd
- Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
- Colorado Blood Cancer Institute
- +279 more
Organization Involved with Phase 1 Indications (132)
- GCP-Service International Ltd. & Co. KG
- Herlev Hospital
- University of Utah
- Panacee Hospital Rama 2
- Applied Physiology Research Center
- Athenex, Inc.
- The Alfred Hospital
- Aileron Therapeutics
- University of Science and Technology of China
- Technical University of Denmark
- Kinesis Pharma
- University of British Columbia
- Philogen S.p.A.
- ADIR Association
- K-Group Beta
- Synta Pharmaceuticals Corp.
- Altor Bioscience
- University of Alberta
- Callisto Pharmaceuticals
- Amplyx Pharmaceuticals
- Yiling Pharmaceutical Inc.
- Prospect Creek Foundation
- University of Maryland, College Park
- Erimos Pharmaceuticals
- Gateway for Cancer Research
- Ascenta Therapeutics
- China Academy of Chinese Medical Sciences
- High Impact Clinical Research Support Program
- GEMoaB Monoclonals GmbH
- Hutchison MediPharma
- +102 more
Organization Involved with Other Experimental Indications (13)
- Linkoping University
- Swiss National Science Foundation
- Integrated Community Oncology Network
- Shengjing Hospital
- Lund University
- MacroGenics
- Immunex
- West Virginia University
- ESP Pharma
- Karolinska Institute
- National Institute on Aging (NIA)
- Association for Training, Education, and Research in Hematology, Immunology, and Transplantation
- Medical University of Vienna